The shares that may be repurchased represent the lesser of $10 million in cost or 10 percent of the public float or 2,161,261 shares. As of August 16, 2006, Xantrex had 28,836,293 common shares issued and outstanding of which approximately 21,612,610 were estimated under applicable rules to be in the public float. For the NCIB which commenced on August 22, 2005, the Company purchased 1,159,600 Common Shares for cancellation through the facilities of the Toronto Stock Exchange at an average price of CDN$8.27 per share.

Purchases under the renewed NCIB are expected to commence on August 22, 2006, and will continue for one year (to August 21, 2007) or until Xantrex announces termination of the bid. Xantrex will pay prevailing market prices at the time of purchase for the shares and purchases will be made in the open market through the facilities of the TSX in accordance with applicable rules and policies. All shares purchased will be cancelled.

"Xantrex is focused on the execution of our growth strategy and improving our financial performance. The renewal of our normal course issuer bid using a portion of our capital is consistent with our objective of creating value for our shareholders," said Mossadiq S. Umedaly, Xantrex’s Chairman.

Note that this news release contains forward-looking statements related to Xantrex Technology Inc. Such statements reflect the current views of Xantrex with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in these forward-looking statements.